Nektar Therapeutics [NKTR] stock prices are up 5.61% to $1.13 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The NKTR shares have gain 13.00% over the last week, with a monthly amount drifted -11.02%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Nektar Therapeutics [NASDAQ: NKTR] stock has seen the most recent analyst activity on November 04, 2024, when Piper Sandler initiated its Overweight rating and assigned the stock a price target of $7. On June 28, 2024, Rodman & Renshaw initiated with a Buy rating and assigned a price target of $2 on the stock. TD Cowen upgraded its rating to a Outperform. Jefferies upgraded its rating to Hold for this stock on May 10, 2023, and downed its price target to $1. In a note dated February 24, 2023, Jefferies downgraded an Underperform rating on this stock and revised its target price from $3.20 to $1.50.
The stock price of Nektar Therapeutics [NKTR] has been fluctuating between $0.42 and $1.93 over the past year. Currently, Wall Street analysts expect the stock to reach $16.75 within the next 12 months. Nektar Therapeutics [NASDAQ: NKTR] shares were valued at $1.13 at the most recent close of the market. An investor can expect a potential return of 1382.3% based on the average NKTR price forecast.
Analyzing the NKTR fundamentals
The Nektar Therapeutics [NASDAQ:NKTR] reported sales of 93.14M for trailing twelve months, representing a drop of -0.08%. Gross Profit Margin for this corporation currently stands at 0.68% with Operating Profit Margin at -1.46%, Pretax Profit Margin comes in at -1.81%, and Net Profit Margin reading is -1.81%. To continue investigating profitability, this company’s Return on Assets is posted at -0.55, Equity is -1.74 and Total Capital is -0.57.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.0900 points at the first support level, and at 1.0500 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.1600, and for the 2nd resistance point, it is at 1.1900.
Ratios To Look Out For
It’s worth pointing out that Nektar Therapeutics [NASDAQ:NKTR]’s Current Ratio is 4.24. Also, the Quick Ratio is 4.24, while the Cash Ratio stands at 0.45. Considering the valuation of this stock, the price to sales ratio is 2.36, the price to book ratio is 4.26.
Transactions by insiders
Recent insider trading involved Zalevsky Jonathan, Chief R&D Officer, that happened on Nov 19 ’24 when 7785.0 shares were sold. Chief Legal Officer, Wilson Mark Andrew completed a deal on Nov 19 ’24 to sell 6407.0 shares. Meanwhile, President & CEO ROBIN HOWARD W sold 16278.0 shares on Nov 19 ’24.
